GlobalData on MSN
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.
MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback